<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02998931</url>
  </required_header>
  <id_info>
    <org_study_id>1395/670</org_study_id>
    <nct_id>NCT02998931</nct_id>
  </id_info>
  <brief_title>Trial of Enteral Glutamine on Clinical Outcomes in Critically Ill Patients</brief_title>
  <official_title>Effects of Enteral Glutamine on Inflammatory Response, Immune System Function and Clinical Outcomes in Hospitalized Patients With Enteral Feeding in Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glutamine supplementation has beneficial effects on morbidity and mortality in critically ill
      patients, possibly in part through an attenuation of the proinflammatory cytokine response
      and a Immune function. In this trial intensive care unit patients with enteral feeding will
      receive either enteral glutamine or maltodextrin as placebo for 28 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double blind, controlled trial will be conducted in general intensive care unit
      (ICU) in Tehran, Iran. After a full review of the inclusion and exclusion criteria and
      explanation of the risks and benefits of the study, written consent form will be completed.
      The participants are 200 eligible hospitalized patients with enteral feeding in ICU, aged â‰¥
      18 years. Intervention patients will be received 0.3 g/kg/day of glutamine along with enteral
      formula for 28 days and control patients will be received maltodextrin along with enteral
      formula for 28 days. Patients will be evaluated for occurrence of new infection, organ
      failure, duration of stay in ICU, 28 days and 6 months mortality and inflammatory and immune
      markers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of infection</measure>
    <time_frame>Day 28</time_frame>
    <description>Incidence of infections</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Inflammatory Markers</measure>
    <time_frame>baseline, Day 5, Day 10</time_frame>
    <description>Inflammatory factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Immunity Markers</measure>
    <time_frame>baseline, Day 5, Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in ICU</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day Mortality</measure>
    <time_frame>Day 28</time_frame>
    <description>Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month mortality</measure>
    <time_frame>month 6</time_frame>
    <description>month 6</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum Glutamin</measure>
    <time_frame>baseline, Day 5, Day 10</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Critical Illness</condition>
  <condition>Enteral Nutrition</condition>
  <condition>Multiple Organ Failure</condition>
  <condition>Infection Complication</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Glutamin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention patients will be received enteral formula and glutamine 0.3 g/kg/day given via nasogastric tube as boluses q 4hrs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>maltodextrin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glutamin</intervention_name>
    <description>Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs</description>
    <arm_group_label>Glutamin</arm_group_label>
    <other_name>L-glutamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>Maltodextrin mixed with water given via NG tube Q 4 hours</description>
    <arm_group_label>maltodextrin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (&gt;18 years old) admitted to ICU

          -  Start of study intervention within 48 hours after ICU admission

          -  Expected to require enteral nutrition for at least 72 hours aiming for full enteral
             nutrition and receive at least 80 percent of enteral formula during the first 48 hour

          -  Written informed consent of patient or written informed consent of legal
             representative

        Exclusion Criteria:

          -  Enrollment in a related ICU interventional study

          -  Requiring other specific enteral nutrition for medical reason

          -  Death or Discharge before 5th day

          -  Having any contra-indication to receive enteral nutrition

          -  Pregnant patients or lactating with the intent to breastfeed

          -  Requiring other specific enteral nutrition for medical reason

          -  BMI &lt;18 or &gt; 40.0 kg/m2

          -  Have life expectancy of &lt;6 mo

          -  Patients who are moribond

          -  Liver cirrhosis- Child's class C liver disease

          -  Have seizure disorder requiring anticonvulsant

          -  History of allergy or intolerance to the study product components

          -  Receiving glutamine during two weeks before start study product

          -  Have other reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zahra Vahdat Shariatpanahi, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zahra Vahdat Shariatpanahi, MD, PhD</last_name>
    <phone>00989122038186</phone>
    <email>nutritiondata@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zahra vahdat shariatpanahi, MD, PhD</last_name>
      <phone>00989122038186</phone>
      <email>nutritiondata@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shohada Tajrish Hospital</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zahra Vahdat Shariatpanahi, MD.Ph.D</last_name>
      <email>nutritiondata@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>van Zanten AR, Sztark F, Kaisers UX, Zielmann S, Felbinger TW, Sablotzki AR, De Waele JJ, Timsit JF, Honing ML, Keh D, Vincent JL, Zazzo JF, Fijn HB, Petit L, Preiser JC, van Horssen PJ, Hofman Z. High-protein enteral nutrition enriched with immune-modulating nutrients vs standard high-protein enteral nutrition and nosocomial infections in the ICU: a randomized clinical trial. JAMA. 2014 Aug 6;312(5):514-24. doi: 10.1001/jama.2014.7698.</citation>
    <PMID>25096691</PMID>
  </reference>
  <reference>
    <citation>Heyland D, Muscedere J, Wischmeyer PE, Cook D, Jones G, Albert M, Elke G, Berger MM, Day AG; Canadian Critical Care Trials Group. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med. 2013 Apr 18;368(16):1489-97. doi: 10.1056/NEJMoa1212722. Erratum in: N Engl J Med. 2013 May 9;368(19):1853. Dosage error in article text..</citation>
    <PMID>23594003</PMID>
  </reference>
  <reference>
    <citation>McClave SA, Taylor BE, Martindale RG, Warren MM, Johnson DR, Braunschweig C, McCarthy MS, Davanos E, Rice TW, Cresci GA, Gervasio JM, Sacks GS, Roberts PR, Compher C; Society of Critical Care Medicine; American Society for Parenteral and Enteral Nutrition. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 2016 Feb;40(2):159-211. doi: 10.1177/0148607115621863. Erratum in: JPEN J Parenter Enteral Nutr. 2016 Nov;40(8):1200.</citation>
    <PMID>26773077</PMID>
  </reference>
  <reference>
    <citation>Kreymann KG, Berger MM, Deutz NE, Hiesmayr M, Jolliet P, Kazandjiev G, Nitenberg G, van den Berghe G, Wernerman J; DGEM (German Society for Nutritional Medicine), Ebner C, Hartl W, Heymann C, Spies C; ESPEN (European Society for Parenteral and Enteral Nutrition). ESPEN Guidelines on Enteral Nutrition: Intensive care. Clin Nutr. 2006 Apr;25(2):210-23. Epub 2006 May 11.</citation>
    <PMID>16697087</PMID>
  </reference>
  <reference>
    <citation>McQuiggan M, Kozar R, Sailors RM, Ahn C, McKinley B, Moore F. Enteral glutamine during active shock resuscitation is safe and enhances tolerance of enteral feeding. JPEN J Parenter Enteral Nutr. 2008 Jan-Feb;32(1):28-35.</citation>
    <PMID>18165444</PMID>
  </reference>
  <reference>
    <citation>Hall JC, Dobb G, Hall J, de Sousa R, Brennan L, McCauley R. A prospective randomized trial of enteral glutamine in critical illness. Intensive Care Med. 2003 Oct;29(10):1710-6. Epub 2003 Aug 16.</citation>
    <PMID>12923621</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2016</study_first_submitted>
  <study_first_submitted_qc>December 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2016</study_first_posted>
  <last_update_submitted>July 16, 2017</last_update_submitted>
  <last_update_submitted_qc>July 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University</investigator_affiliation>
    <investigator_full_name>Zahra Vahdat Shariatpanahi</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Glutamin</keyword>
  <keyword>Enteral Nutrition</keyword>
  <keyword>Intensive Care Unit</keyword>
  <keyword>Critical Care Outcomes</keyword>
  <keyword>inflammatory</keyword>
  <keyword>Immune System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Multiple Organ Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

